Last updated: February 14, 2026
What is the current market status and price projection for NDC 72252-0515?
NDC 72252-0515 refers to a specific drug product, which needs identification for context. Based on publicly available data, this NDC corresponds to Rebif (interferon beta-1a), used in multiple sclerosis (MS) treatment. The following analysis focuses on the drug's market size, competitive landscape, pricing trends, and future price projections.
What is the current market size for Rebif (NDC 72252-0515)?
Market Overview
The global multiple sclerosis (MS) treatment market is valued at approximately $24 billion in 2022, with interferon beta therapies accounting for roughly 25% of the segment. Rebif, a branded interferon beta-1a drug, retains notable market share within interferon therapies.
U.S. Market Share and Usage
In the United States, MS treatments total about $7 billion annually. Rebif's estimated share is 20-25%, translating to roughly $1.4-$1.75 billion in annual sales.
Key Regulatory and Competitive Factors
- Approved indications: Relapsing-remitting MS.
- Market competitors: Avonex (interferon beta-1a), Betaseron/Betaferon (interferon beta-1b), and oral disease-modifying therapies (e.g., Tecfidera, Aubagio).
Market Trends
- Growing patient base with an estimated 1 million MS patients in the U.S.
- Increasing adoption of oral therapies, impacting injectable drug sales.
- Biologics like Rebif face pricing pressures due to biosimilar entries and healthcare cost containment policies.
What are the pricing trends of NDC 72252-0515?
Current Pricing
As of Q1 2023, the average wholesale price (AWP) for Rebif (22 mcg, 50-dose vial) is approximately $3,200 per dose. The typical regimen involves three weekly injections, leading to:
| Dosage |
Doses per year |
Approximate annual cost |
| 22 mcg |
150 doses |
$480,000 |
Reimbursement Dynamics
- Average sales price (ASP): Approximately $2,500–$3,000 per dose.
- Medicare and Medicaid reimbursement rates slightly lower than AWP.
- Patient out-of-pocket costs vary based on insurance, typically $50–$200 per injection.
Biosimilar and Competition Impact
- Biosimilar versions of interferon beta-1a marketed in Europe and planned for U.S. approval could reduce Rebif's price by 15–25% over the next 2-3 years.
- Price reductions already observed following biosimilar launches in Europe (e.g., Samsung Bioepis's Ontruzant).
What are future price projections for NDC 72252-0515?
Short-term Outlook (Next 1-2 Years)
- No significant price increases expected due to market saturation and biosimilar competition.
- Cost pressure from payers likely to continue, with rebates and discounts increasing.
- Estimated price decline of 5–10% in wholesale and retail pricing.
Long-term Outlook (Next 3-5 Years)
- Potential price stabilization or slight decrease if biosimilar approvals occur and gain market share.
- Entry of biosimilars could cause a 20–30% price decrease in the generic segment.
- Healthcare policies emphasizing cost savings could further depress pricing.
Variables Influencing Price Movements
- Biosimilar approval and uptake.
- Medicaid and Medicare policy changes affecting rebates.
- Patent expiry timelines (original patent expired in 2024 for the original formulation).
- Innovation in MS treatments, including oral and infusion therapies.
What are the key uncertainties affecting the market and price?
- Accelerated biosimilar approvals impacting Rebif's market share.
- Regulatory decisions influencing the line of competition.
- Insurance reimbursement policies and patient access programs.
- Advances in MS therapy protocols shifting patient preferences.
Key Takeaways
- Market size: Approximately $1.4–$1.75 billion annually in the U.S. for Rebif.
- Pricing: Current wholesale price around $3,200 per dose; annual treatment costs close to $480,000.
- Trend: Slight downward pressure anticipated, with potential 15–25% price reductions through biosimilar competition over 3 years.
- Drivers: Patent expiration, biosimilar approval, healthcare policy, and evolving treatment guidelines.
- Risks: Slower biosimilar adoption, policy shifts favoring cost containment, and evolving treatment options.
FAQs
Q1: When will biosimilars for Rebif likely enter the U.S. market?
A1: European biosimilars are available; U.S. approvals are anticipated within 1-2 years, contingent on FDA review and patent litigations.
Q2: How does Rebif's price compare to other MS therapies?
A2: Rebif is among the most expensive injectable MS therapies, similar in cost to Avonex but higher than oral options like Tecfidera.
Q3: What are the primary factors influencing Rebif's market share?
A3: Patent status, biosimilar competition, physician and patient preferences, and insurance coverage.
Q4: Are there any ongoing patent litigations affecting Rebif?
A4: Patent expiry for Rebif's original formulation occurred in 2024, opening the path for biosimilar competition.
Q5: How might healthcare policies impact the future pricing of Rebif?
A5: Payers' emphasis on cost savings and potential regulatory measures could lead to mandated price reductions and increased rebate requirements.
References
- IQVIA. (2022). MS Market Analysis.
- Drug Topics. (2023). Rebif Pricing Trends.
- FDA. (2022). Biosimilar Approvals.
- GlobalData. (2023). Interferon Beta Competitive Landscape.
- CMS. (2023). Medicare Reimbursement Policies.
